Caron A. Jacobson
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Caron A. Jacobson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:29 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03636503 · Rituximab + Immunotherapy in Follicular LymphomaDana-Farber Cancer Institute · terminated · Follicular Lymphoma · principal investigator
- Ph2NCT02572453 · Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCLNational Cancer Institute (NCI) · terminated · Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NCI ETCTN Pittsburgh Cancer Consortium (PCC)UM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani, Liza Cosca Villaruz · fiscal years 2014 to 2026Named on NCT02572453
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNUM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE, Geoffrey I. Shapiro · fiscal years 2014 to 2026Named on NCT02572453
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:29 UTC. The ranking covers the 200 most relevant of 35 PubMed records, and a shared surname and initials can bring in a namesake. All 35 on PubMed
- 5,007 citationsRCR 162.2
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.Lancet Oncol · 20191,947 citationsRCR 70.8
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.N Engl J Med · 20201,539 citationsRCR 62.3
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.N Engl J Med · 20221,394 citationsRCR 94.5
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.Lancet Oncol · 2022591 citationsRCR 38.4
- Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.N Engl J Med · 2023428 citationsRCR 35.5
- 260 citationsRCR 7.9
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.Nat Commun · 2020249 citationsRCR 8.4
- Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.Br J Haematol · 2021196 citationsRCR 10.0
- CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.Blood · 2021192 citationsRCR 8.5